Tags

Type your tag names separated by a space and hit enter

Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
Arterioscler Thromb Vasc Biol. 2005 Dec; 25(12):2600-7.AT

Abstract

OBJECTIVE

The goal of this study was to characterize the effect of microcoated fenofibrate (160 mg/day for 6 months) on plasma lipoprotein composition and kinetics in 2 patients with complete hepatic lipase (HL) deficiency.

METHODS AND RESULTS

Fenofibrate treatment normalized the plasma lipoprotein profile of patients with complete HL deficiency, as evidenced by significant reductions in the plasma concentration of cholesterol (-49%) and triglycerides (-82%) and a significant increase in low-density lipoprotein (LDL) size (251.5+/-1.8 versus 263.5+/-0.7 A). The in vivo kinetics of very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and LDL apolipoprotein (apo)B-100 and plasma apoA-I and apoA-II were studied using a primed-constant infusion of L-[5,5,5-D3]-leucine for 12 hours in the fasted state. Fenofibrate treatment in complete HL-deficient patients substantially decreased plasma concentrations of VLDL, IDL, and LDL apoB-100 attributable to important increases in VLDL (+325%), IDL (+129%), and LDL (+218%) apoB-100 fractional catabolic rates (FCR). IDL apoB-100 FCR nevertheless remained 60% lower after treatment compared with values obtained in controls (n=5). The kinetics of plasma apoA-I and apoA-II as well as the capacity of total plasma and of high-density lipoprotein particles to efflux cellular cholesterol from normal human skin fibroblasts was not altered by fenofibrate.

CONCLUSIONS

Fenofibrate therapy exerts a pronounced antiatherogenic effect on triglyceride-rich lipoproteins even in the complete absence of HL.

Authors+Show Affiliations

Institute on Nutraceuticals and Functional Foods, Laval University, Québec, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16224048

Citation

Ruel, Isabelle L., et al. "Effect of Fenofibrate On Plasma Lipoprotein Composition and Kinetics in Patients With Complete Hepatic Lipase Deficiency." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 12, 2005, pp. 2600-7.
Ruel IL, Lamarche B, Mauger JF, et al. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency. Arterioscler Thromb Vasc Biol. 2005;25(12):2600-7.
Ruel, I. L., Lamarche, B., Mauger, J. F., Badellino, K. O., Cohn, J. S., Marcil, M., & Couture, P. (2005). Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(12), 2600-7.
Ruel IL, et al. Effect of Fenofibrate On Plasma Lipoprotein Composition and Kinetics in Patients With Complete Hepatic Lipase Deficiency. Arterioscler Thromb Vasc Biol. 2005;25(12):2600-7. PubMed PMID: 16224048.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency. AU - Ruel,Isabelle L, AU - Lamarche,Benoît, AU - Mauger,Jean-François, AU - Badellino,Karen O, AU - Cohn,Jeffrey S, AU - Marcil,Michel, AU - Couture,Patrick, Y1 - 2005/10/13/ PY - 2005/10/15/pubmed PY - 2006/1/21/medline PY - 2005/10/15/entrez SP - 2600 EP - 7 JF - Arteriosclerosis, thrombosis, and vascular biology JO - Arterioscler Thromb Vasc Biol VL - 25 IS - 12 N2 - OBJECTIVE: The goal of this study was to characterize the effect of microcoated fenofibrate (160 mg/day for 6 months) on plasma lipoprotein composition and kinetics in 2 patients with complete hepatic lipase (HL) deficiency. METHODS AND RESULTS: Fenofibrate treatment normalized the plasma lipoprotein profile of patients with complete HL deficiency, as evidenced by significant reductions in the plasma concentration of cholesterol (-49%) and triglycerides (-82%) and a significant increase in low-density lipoprotein (LDL) size (251.5+/-1.8 versus 263.5+/-0.7 A). The in vivo kinetics of very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and LDL apolipoprotein (apo)B-100 and plasma apoA-I and apoA-II were studied using a primed-constant infusion of L-[5,5,5-D3]-leucine for 12 hours in the fasted state. Fenofibrate treatment in complete HL-deficient patients substantially decreased plasma concentrations of VLDL, IDL, and LDL apoB-100 attributable to important increases in VLDL (+325%), IDL (+129%), and LDL (+218%) apoB-100 fractional catabolic rates (FCR). IDL apoB-100 FCR nevertheless remained 60% lower after treatment compared with values obtained in controls (n=5). The kinetics of plasma apoA-I and apoA-II as well as the capacity of total plasma and of high-density lipoprotein particles to efflux cellular cholesterol from normal human skin fibroblasts was not altered by fenofibrate. CONCLUSIONS: Fenofibrate therapy exerts a pronounced antiatherogenic effect on triglyceride-rich lipoproteins even in the complete absence of HL. SN - 1524-4636 UR - https://www.unboundmedicine.com/medline/citation/16224048/Effect_of_fenofibrate_on_plasma_lipoprotein_composition_and_kinetics_in_patients_with_complete_hepatic_lipase_deficiency_ L2 - https://www.ahajournals.org/doi/10.1161/01.ATV.0000190700.76493.bb?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -